HCPCS Code J2010: Lincomycin HCl injection billing guide

Key takeaways

HCPCS Code J2010 covers the injection of lincomycin hydrochloride (Lincocin), up to 300 mg, and one unit equals one 300 mg dose.

NDC reporting is mandatory on outpatient drug claims for J2010 under CMS Medicare Claims Processing Manual Chapter 17.

The NDC on the claim comes from the vial that was administered, never from the supplier invoice.

Modifier applicability, including JW and JZ for drug wastage, depends on payer policy and setting. Verify with your payer before applying either.

Practice management software like Pabau supports HCPCS J-code workflows, including drug documentation and injectable claim submission.

HCPCS Code J2010 covers the injection of lincomycin hydrochloride (Lincocin), up to 300 mg. It sits in the HCPCS Level II J-code range that CMS maintains for drugs given by injection or infusion.

Denials on J2010 usually trace back to the National Drug Code rather than the J-code. Every outpatient drug claim has to carry the 11-digit NDC from the vial that was administered. Good claims management software pulls that number straight through to the claim line.

This reference covers the code definition, Medicare payment rates, NDC mapping, place-of-service rules, and the ICD-10 diagnosis codes paired with J2010 claims.

HCPCS Code J2010: Definition and code details

According to the Centers for Medicare and Medicaid Services (CMS), HCPCS Code J2010 describes the injection of lincomycin hydrochloride (HCl), up to 300 mg. It belongs to the J-code range of HCPCS Level II.

That range covers drugs given by injection, infusion, and other non-oral routes outside the standard CPT framework. Level II also holds service and supply codes beyond the drug range, such as the therapy services billed under G0152.

Drug background: Lincomycin HCl injection

Lincomycin HCl (Lincocin) is an injectable antibiotic in the lincosamide class. It is FDA-approved for serious infections caused by susceptible gram-positive bacteria, where less potentially toxic alternatives are inappropriate.

Clinicians typically reach for it in streptococcal, staphylococcal, or pneumococcal infections when penicillin-based options cannot be used. Oral absorption is inconsistent in severe infections, so the parenteral form is used in inpatient and outpatient infusion settings.

• Drug class: Lincosamide antibiotic
• Brand name: Lincocin (lincomycin HCl injection)
• Typical indications: Serious streptococcal, staphylococcal, and pneumococcal infections in patients unable to tolerate penicillin
• Route of administration: Intramuscular (IM) or intravenous (IV) injection
• Maximum billing unit under J2010: Up to 300 mg per claim line

Off-label or broader applications sit outside the FDA-approved labeling. Claims for diagnoses the prescribing information does not support carry a heightened denial risk. Medical necessity documentation matters on every J2010 submission.

Medicare fee schedule and reimbursement for J2010

Payment rates for J2010 are published annually by CMS under the Medicare Physician Fee Schedule (MPFS) and the Hospital Outpatient Prospective Payment System (OPPS). Rates change each calendar year.

Always verify current figures using the CMS Physician Fee Schedule look-up tool before building fee estimates into your revenue cycle.

Practices administering lincomycin in an outpatient infusion suite should check the ASC payment indicator in the current CMS OPPS Addendum B file. Indicators change annually, so what applied last year may not apply now.

IV therapy EMR software that integrates with fee-schedule data can flag those changes before they hit the claim.

NDC codes associated with J2010

CMS mandates NDC reporting on outpatient drug claims under Medicare Claims Processing Manual Chapter 17. A J2010 claim submitted without a valid NDC is likely to be rejected or denied by Medicare and many commercial payers.

An EMR built for IV therapy should capture the NDC at the point of administration so it flows into the claim line.

The NDC must appear on the claim in 11-digit format (5-4-2), with the qualifier N4 in the appropriate field. That means Box 24 on the CMS-1500, or FL 43 on the UB-04.

Practice management software like Pabau captures the administered lot, dose, and drug through digital clinical forms. The table below lists representative product types associated with lincomycin HCl injection.

NDC numbers are manufacturer- and lot-specific, so this table gives representative product types only. Pull the exact NDC from the vial label at the time of administration and record it in the patient chart.

Check it against the FDA NDC directory or the AAPC Codify HCPCS lookup before submitting.

Billing and coding guidelines for HCPCS Code J2010

Claims for lincomycin injection under J2010 follow the standard rules for HCPCS Level II injectable drug codes. Billing staff should review the intake documentation behind each administration before submitting. The core billing rules are:

1. Units of service: One unit of J2010 equals up to 300 mg of lincomycin HCl. If the patient receives 600 mg, report 2 units. Never bill fractional units. Round up to the next whole unit between standard dose increments.
2. NDC reporting (mandatory): Include the 11-digit NDC in N4 format on every outpatient drug claim. CMS requires this under the Medicare Claims Processing Manual. Omitting the NDC is the leading cause of J2010 claim rejections.
3. Claim form field placement: On the CMS-1500, the NDC goes in Box 24 (shaded area) with qualifier N4. On the UB-04, it goes in Form Locator 43 with the same qualifier.
4. Modifier JW/JZ (drug wastage): Applicability depends on payer policy and on whether the vial is single-dose or multi-dose. CMS publishes general drug wastage guidance, but your payer’s LCD decides whether JW or JZ belongs on a J2010 line. Confirm before you append either one.
5. Medical necessity documentation: The record needs the treating physician’s order, the diagnosis, and the clinical rationale for lincomycin over a less potentially toxic alternative. Get all three in before the claim goes out.
6. Administration code: Bill the injection or infusion administration code alongside J2010, such as 96365 for the initial hour of an IV infusion. The drug and the administration are separate line items.

Practices managing injectable drug claims across several payers lose time re-keying the same detail twice. Prescription management software that tracks administered doses by product can automate the crosswalk between the vial and the J-code on the claim.

ICD-10 diagnosis codes commonly paired with J2010

J2010 must be paired with an ICD-10-CM diagnosis code that establishes medical necessity. The table below lists conditions commonly treated with lincomycin injection. These are examples of diagnoses reported alongside J2010 claims, and they are not a guarantee of coverage.

Payer-specific Local Coverage Determinations (LCDs) and National Coverage Determinations (NCDs) govern what is covered for each diagnosis.

Deep soft-tissue infections often bring a procedure onto the same claim, such as the debridement reported under 11043. Practices that give injectable antibiotics in outpatient settings need HIPAA-compliant practice software. It should link the drug, the diagnosis code, and the provider’s order in one auditable record.

Related HCPCS J-codes for injectable antibiotics

Selecting the correct J-code for an injectable antibiotic matters because each code maps to a specific drug, dose unit, and fee schedule amount.

The table below also works as a crosswalk when a payer questions whether J2010 was the right pick over a similar code. Dose units differ across the range, so J2323 is reported per milligram while J2010 is reported per 300 mg.

How Pabau keeps NDC detail on the claim

In most practices the drug is recorded in the chart while the claim is built somewhere else. The NDC gets typed twice, once from the vial and once from an invoice or someone’s memory of what was pulled from the shelf. When the two disagree, the payer sees a mismatch and the claim comes back.

Pabau closes that loop. The clinician records the drug, dose, and lot against the treatment note at the point of administration. The same detail carries into the claim line. Nobody reconstructs the record from a supply order three days later, so corrected claims and payment delays drop away.

Injectables are not limited to infusion suites. The same record works in a travel clinic giving injectable vaccines, where the vial detail decides whether the drug line gets paid.

Simplify injectable drug billing with Pabau

Pabau’s claims management software supports HCPCS J-code workflows, drug-level documentation, and multi-payer claim submission from one platform. See how it fits your practice.

Book a demo

Conclusion

J2010 is a narrow code, and the claim usually clears when two things hold. The NDC has to match the vial that went into the patient. The record has to show why lincomycin beat a gentler alternative.

Both come down to capture, not coding. Fix the moment the drug is recorded and the J-code stops being the problem. Book a demo to see how Pabau handles injectable drug documentation and claim submission for your practice.

Continue your research

Need the codes your team looks up daily in one place? medical coding cheat sheet collects the common CPT, ICD-10, and HCPCS references into a single printable file.

Billing an infusion rather than an injection? J7120 walks through how infusion solutions are reported and where the units trip billers up.

Running drug therapy in the patient’s home? S9379 covers per-diem home infusion therapy billing and the documentation payers expect with it.

Billing the pump as well as the drug? K0455 explains how infusion pump rental is coded and when it sits on the same claim.

Billing outside the US system? MBS item numbers explains how Australian practices claim for services, and how that structure differs from HCPCS.

Frequently asked questions